Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Rapport Therapeutics (NASDAQ:RAPP) reported robust Phase II data for RAP-219 in drug-resistant focal epilepsy, showing a statistically significant 78% median reduction in clinical seizures and a 24% seizure freedom rate, alongside a highly differentiated tolerability profile with a low 10% discontinuation rate. This 'best-in-class' profile, driven by a novel mechanism and low drug-drug interaction risk, is expected to enable broad adoption by general neurologists, significantly expanding the market opportunity to potentially multi-billion dollar sales. The company is well-funded into H2 2029, supporting upcoming end-of-Phase II FDA discussions, planned Q3 2026 initiation of two parallel Phase III studies, and development of a long-acting injectable formulation.

Analysis

Rapport Therapeutics' Phase II data for RAP-219 in treatment-resistant focal epilepsy presents a compelling, best-in-class profile that significantly strengthens its commercial outlook. The drug achieved a statistically significant 78% median reduction in clinical seizures and a 24% seizure freedom rate in a highly refractory patient population, with results validated by an objective electrographic biomarker. This strong efficacy is complemented by a differentiated tolerability profile, featuring a low 10% discontinuation rate and an absence of burdensome adverse events like aggression or significant ataxia associated with competing drugs. Consequently, management projects a major expansion of the target market beyond specialists to general neurologists, shifting the peak sales potential from $1.5 billion to a multi-billion dollar opportunity. The company is well-capitalized, with a recent financing extending its cash runway into the second half of 2029, which fully funds the planned initiation of two parallel Phase III studies in Q3 2026 and the development of a potentially transformational long-acting injectable (LAI) formulation.

Key Decisions for Investors

• The robust Phase II data represents a significant clinical de-risking event for RAP-219, supporting a bullish stance on the asset's potential to capture a multi-billion dollar market share in epilepsy.
• Investors should monitor for key catalysts including feedback from the end-of-Phase II meeting with the FDA by year-end and the formal initiation of Phase III trials in Q3 2026, which will be critical for the regulatory pathway.
• Recognize that the company is well-funded through all pivotal trial milestones into H2 2029, mitigating near-term financing risk and allowing focus on long-term value drivers like the long-acting injectable and expansion into bipolar disorder.